Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023418 (leukemia)
 93,477 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A case of primary malignant lymphoma of the bladder is reported. A 73-year-old woman was admitted to our clinic with the chief complaint of asymptomatic gross hematuria on January 11, 1982. Preoperative examinations with cystoscopy, DIP, cystogram, CT scan, ultrasonography and transurethral biopsy suggested a non-epithelial tumor of the bladder. Partial cystectomy was performed on March 31, 1982. Histological diagnosis was diffuse lymphoma, medium-sized cell type by the classification of LSG (The lymphoma-leukemia study group of Japan). One month later, she was treated with VEPA therapy, which consisted of vincristine, cyclophosphamide (Endoxan), prednisolone and adriamycin. Postoperative course was uneventful and she has been doing well without any clinical evidence of recurrence during the period of 11 months following the operation.
 ...
PMID:[Primary malignant lymphoma of the urinary bladder: report of a case]. 667 43

A series of acridine monosubstituted derivatives of the antitumour agent amsacrine [4'-(9-acridinylamino)methanesulphon-m-anisidide] has been tested for activity against intraperitoneally inoculated P388 leukaemia and intravenously inoculated Lewis lung carcinoma growing in DBA/2J X C57BL/6J mice, and treated using a q4d X 3 intraperitoneal injection schedule. Whereas all derivatives tested exhibited moderate to high activity towards the leukaemia, activity against the lung tumour varied from inactive to curative. Amsacrine itself displayed low but statistically significant activity. Cyclophosphamide and 2-beta-D-ribofuranosylthiazole-4-carboxamide (tiazofurin) were highly active. 5-Fluorouracil was active but doxorubicin, daunorubicin, ametantrone and mitoxantrone showed no significant activity. Since the Lewis lung carcinoma is responsive to a high proportion of agents active against solid tumours in the clinic, it is concluded that some derivatives of amsacrine could be considerably more active than amsacrine itself against human solid tumours.
 ...
PMID:Divergent activity of derivatives of amsacrine (m-AMSA) towards Lewis lung carcinoma and P388 leukaemia in mice. 668 94

Carbon tetrachloride is an hepatotoxin that depresses hepatic microsomal cytochrome P-450 and other enzyme activities. Cyclophosphamide is an anticancer drug that is activated by hepatic microsomal cytochrome P-450, while the products of cyclophosphamide metabolism by cytochrome P-450 can be metabolized by other hepatic enzymes. Carbon tetrachloride pretreatment has been found to increase the in vivo antitumor activity of cyclophosphamide against murine leukemia P-388. Carbon tetrachloride did not, however, affect the direct cytotoxicity of cyclophosphamide or 4-hydroxycyclophosphamide to cells in culture. Pharmacokinetic studies in mice revealed a delayed plasma disappearance of cyclophosphamide after carbon-tetrachloride pretreatment with an apparent initial half-time of 20.4 min compared to 9.0 min in non carbon-tetrachloride-pretreated mice. Plasma levels of total alkylating activity and plasma 4-hydroxycyclophosphamide increased more slowly and reached a lower peak, but were maintained for a longer time period in mice pretreated with carbon-tetrachloride than in untreated mice. The half-life for plasma elimination of 4-hydroxycyclophosphamide in untreated mice was 12 min and in carbon-tetrachloride-pretreated mice 27 min. There was, however, no difference in the area under the curve for either plasma total alkylating activity or plasma 4-hydroxycyclophosphamide between the two groups. It is suggested that prolonged exposure of tumor cells to 4-hydroxycyclophosphamide might be responsible for the increased antitumor activity of cyclophosphamide following carbon-tetrachloride pretreatment.
 ...
PMID:Carbon tetrachloride-induced increase in the antitumor activity of cyclophosphamide in mice: a pharmacokinetic study. 670 34

E-N-L-trimethyl lysine (TML) decreases the toxicity of Vincristin, Cyclophosphamide and Doxorubicin (Adriamycin) when administered simultaneously to healthy mice. Simultaneous treatment of L1210 ascites leukemia bearing mice with 100 mg/kg TML and 2, 2.5, 3.2, 3.5, 4 mg/kg Vincristin or 10-15; 20 mg/kg Doxorubicin increases significantly the survival of the animals when compared with untreated and Vincristin or Doxorubicin treated mice. Repeated impulse treatment of S-180 subcutaneous sarcoma with 100 mg/kg TML and 50-100 mg/kg Cyclophosphamide results in a significantly higher surviving time and surviving rate than Cyclophosphamide treatment alone.
 ...
PMID:Combined effect of cytostatic drugs and E-N-L-trimethyl lysine in healthy and transplantable tumor bearing mice. 681 49

Central nervous system regulation of endocrine functions is mediated by neurotransmitters, via hypothalamic hypophysiotropic factors which in turn control anterior pituitary functions. The evidence of serotonergic-endocrine interrelations with regard to adrenal, thyroid, gonadal and prolactin functions is fast accumulating. Our study extends the importance of those interrelations to some functions of the immune system. Multiple administration of 5-hydroxytryptamine(serotonin) or its precursor, 5-hydroxy-L-tryptophan(5-HTPH), produces marked depression of T cell dependent, humoral, hemolytic, primary immune response in mice. L-tryptophan, a more distant serotonin precursor, produces slight but significant depression of this immune response. Multiple treatment of mice infected with Friend Leukemia Virus (FLV) with serotonin or 5-HTPH alone or in combination with cyclophosphamide (Cytoxan) results in significant delay of the clinical progression of the infection. L-tryptophan produces a modest but significant improvement. Administration of serotonin or 5-HTPH causes a marked reduction of the thymus weight. It is reasonable to postulate that the described effects result from the thymus involution which affects the T cell compartment of the immune system. This is the consequence of hormonal imbalance caused by the alteration of the serotonin biosynthetic pathway in the brain. The adrenal cortex is not implicated in the mediation of this effect. Since many clinically used drugs affect the serotonin metabolism, the clinical consequences of the resulting alteration of the immunological responsiveness should be considered.
 ...
PMID:Serotonin and its precursors as modulators of the immunological responsiveness in mice. 696 31

Sequential treatment of mice with 5-(3,3'-dimethyl-1-triazeno)-imidazole-4-carboxamide (DTIC) and Cyclophosphamide (Cy) produced long-term inhibition of endogenous cells proliferation in the spleen and impairment of classical allograft response, similar to that obtainable with lethal total body irradiation. The growth of BALB/c bone marrow or of virus-induced LSTRA leukemia of BALB/c origin, was studied comparatively in drug-treated or irradiated histocompatible (BALB/c x DBA/2)F1 or allogeneic C3H/HeN hosts. No splenic resistance of Hh type against bone-marrow cells was detected in C3H recipients, either irradiated or drug-treated, confirming previous studies on the Hh susceptibility of C3H strain. In contrast, strong transplantation resistance was detected in the spleen, liver and lung of the same hosts, irradiated or drug-treated, and challenged with LSTRA cells. It follows that Hh-susceptible mice are competent for mounting a localized radioresistant and drug-resistant response, directed against a virus-induced lymphoma.
 ...
PMID:Differential graft resistance of C3H mice pretreated with antitumor drugs against BALB/c bone marrow or lymphoma cells. 700 59

Seventeen patients with relapsed, acute leukemia were grafted with bone marrow from HLA-identical siblings by the 'Munich Cooperative Group for Bone Marrow Transplantation' during the period from August 1975 to June 1980. The antileukemic and immunosuppressive conditioning treatment consisted of high doses of bischlorethyl nitrosourea, Cytosine-Arabinoside and Cyclophosphamide, as well as, total body irradiation of about 9 Gy (midline body dose) from dual 60Cobalt sources. Methotrexate was given to all patients for prophylaxis of graft-versus-host disease (GvHD). Nine patients received marrow that was treated with anti-T-cell globulin (ATCG) "in vitro".--Crossreacting antibodies against hemopoietic stem cells were removed by absorption. Two of 5 evaluable patients given untreated marrow developed chronic GvHD, while patients given ATCG-treated marrow did not show unequivocal symptoms of GvHD. Six patients are in complete remission one to 33 months following bone marrow transplantation (b.m.t.) Five patients died with relapses of leukemia between 3 1/2 and 24 months following b.m.t., 3 patients died with interstitial pneumonia within 3 months of b.m.t. and 3 patients died with insufficient graft function within 4 weeks of b.m.t. Four of thirteen patients that were grafted more than 6 months ago are presently alive and in continuous complete remission at 11, 14, 29 and 33 months following b.m.t. Our results confirm that longterm remissions can be obtained with b.m.t. in patients with acute leukemia in advanced stage.
 ...
PMID:[Bone marrow transplantation for relapsed, acute leukaemia (author's transl)]. 701 3

The combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue was evaluated in the treatment of relapsed leukemia refractory to normal-dose chemotherapy. Cyclophosphamide was given at a total dose of 4.5 g/m2, BCNU at a dose of 300 mg/m2, and VP-16-213 at a dose of 600 mg/m2. Seven high-dose treatments followed by marrow rescue were administered to six patients. Two patients achieved complete remissions, three had partial remissions, and one achieved a minimal response. The toxicity of this regimen was moderate.
 ...
PMID:Combination of high-dose cyclophosphamide, BCNU, and VP-16-213 followed by autologous marrow rescue in the treatment of relapsed leukemia. 701 23

We compared the cytotoxic effects of cyclophosphamide and iphosphamide on normal hematopoietic colony-forming units (NCFU) and L1210 leukemia colony-forming units (LCFU), using the quantitative spleen colony assay. Cyclophosphamide was more cytotoxic for NCFU than iphosphamide, but both agents had a similar cytotoxic effect on LCFU survival, whether given as a single injection or a 24-hour infusion. Although both agents were less cytotoxic for LCFU when administered in 24-hour infusions, host toxicity indicated that correspondingly larger doses of each agent could be given by infusion. The two agents also exhibited very similar cell-killing kinetics.
 ...
PMID:Comparison of cytotoxic action of iphosphamide and cyclophosphamide. 734 53

The colony forming unit assay was introduced in our laboratory for studies in vivo on the differential effect of new antitumor agents on normal bone marrow and tumor cells, the normal (NCFU) and leukemic (LCFU). To verify the technique the effect of Cyclophosphamide (CY) on the total number and the number of stem cells in bone marrow was examined. Different sensitivity of the mouse normal as compared with leukemic stem cells (leukemia P-388) was shown.
 ...
PMID:Effect of cyclophosphamide on mouse bone marrow and leukemic stem cells. 744 49


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>